Effect of new remedy IMOD [Immunomodulating drug ] on the mortality of patients with severe sepsis. A phase III multicenter study

Phase 3

• Conditions: sepsis; Inflammatory and Immune System - Rheumatoid arthritis

• Registration Number: ACTRN12609000001291
• Lead Sponsor: pars rus

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Severe sepsis with APACHE (Acute Physiology And Chronic Health Evaluation)Score>20 with less than 24 hours after their diagnosis.

Exclusion Criteria

pregnant or lactating person, Age less than 16 years old, high death possibility within 24-48 hours and previous organ transplantation and receiving immunosuppressant drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality at 28 days[28 days]

Secondary Outcome Measures

Name	Time	Method
morbidity(Length of stay, SOFA [Sepsis-related Organ failure Assessment])[90 days]